
Lloyd Trotman
Professor
Cancer Center Deputy Director of Education
Ph.D., University of Zurich, 2001
trotman@cshl.edu | 516-367-5054
We have recently developed the first genetic mouse model for therapy and analysis of metastatic prostate cancer. Now we can test if and how modern concepts of cancer evolution can outperform the 80-year-old standard of care- hormone deprivation therapy-and turn lethal prostate cancer into a curable disease.
Lloyd Trotman’s recent research path begins at his discovery some years ago that the loss of a single copy of a master tumor suppressing gene called PTEN is sufficient to permit tumors to develop in animal models of prostate cancer. His team later found that complete loss of PTEN paradoxically triggers senescence, an arrested state that delays or blocks cancer development in affected cells. These findings explained why many patients only display partial loss of this tumor suppressor when diagnosed with prostate cancer. Now the team is researching ways to restore the PTEN protein levels in these patients. This therapeutic approach could slow disease progression and thus greatly reduce the need for surgical removal of the prostate or similar drastic interventions that carry the risks of incontinence and impotence. Their second approach to combat prostate cancer is to model the lethal metastatic disease in genetically engineered mice. They are developing a novel approach that allows for quick generation and visualization of metastatic disease. The efficacy of existing and novel late-stage therapies, such as antihormonal therapy, can then be tested and optimized in these animals. At the same time, the Trotman lab is exploring the genome alterations associated with metastatic disease and with resistance to therapy. To this end, they use single- and multicell genome sequencing techniques developed at CSHL by Drs. Wigler and Hicks.
2022 Member, AACR Science Education and Career Advancement Committee
2021 Editorial Board member, The Journal of Cell Biology, Rockefeller Press, NY
2020 Editorial Advisory Board member, The EMBO Journal
2014 Pershing Square Sohn Prize
2014 American Cancer Society Scholar
2008 V Foundation Scholar
2007 Rita Allen Foundation Scholar
2006 ASCB Merton R. Bernfield Memorial Award
Bite into this diet and disease quiz
July 5, 2023
Test your knowledge of how diet and nutrition affect health and disease with this short quiz.
Cancer has a lot of nerve
August 22, 2022
Tumors recruit the nervous system to help them spread. Scientists are looking for ways to stop it.
The prostate cancer cell that got away
November 16, 2021
Like finding a needle in a haystack, CSHL scientists can now track prostate cancer in mice from its single cell start and as it spreads.
CSHL Ph.D. program: Graduating class of 2021
August 22, 2021
The CSHL School of Biological Sciences awarded Ph.D. degrees to seven students this year, who describe some of their experiences.
CSHL Association holds its annual meeting
January 29, 2021
The Cold Spring Harbor Laboratory Association welcomes four new directors and thanks three retiring ones.
Cold Spring Harbor Laboratory: Science is hope
December 21, 2020
The Laboratory is a leading research center for genetics, cancer, plant biology, quantitative biology, and neuroscience.
A science career path: Jason Williams
April 24, 2020
He is now a leader at the DNA Learning Center, the place that taught him to love biology in high school.
Congressman Suozzi honors Regeneron scholars at CSHL
February 26, 2020
Congressman Tom Suozzi congratulated Regeneron semi-finalists, including two Partners for the Future, at a ceremony hosted at CSHL.
Fresh insights into prostate cancer surprise Movember crowd
November 22, 2019
For a special “Movember” edition of Cocktails and Chromosomes, Dr. Lloyd Trotman explained what his lab is doing to understand deadly prostate cancers.
Movember with Lloyd Trotman—A Cocktails and Chromosomes talk about prostate cancer
November 19, 2019
In this Movember edition of Cocktails & Chromosomes, learn how new concepts of cancer evolution could turn prostate cancer into a curable disease.
All Publications
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells
Aug 2023 | Nature Cancer | 4(8):1102-1121
Brina, Daniela, Ponzoni, Adele, Troiani, Martina, Calì, Bianca, Pasquini, Emiliano, Attanasio, Giuseppe, Mosole, Simone, Mirenda, Michela, D'Ambrosio, Mariantonietta, Colucci, Manuel, Guccini, Ilaria, Revandkar, Ajinkya, Alajati, Abdullah, Tebaldi, Toma, Donzel, Deborah, Lauria, Fabio, Parhizgari, Nahjme, Valdata, Aurora, Maddalena, Martino, Calcinotto, Arianna, Bolis, Marco, Rinaldi, Andrea, Barry, Simon, Rüschoff, Jan, Sabbadin, Marianna, Sumanasuriya, Semini, Crespo, Mateus, Sharp, Adam, Yuan, Wei, Grinu, Mathew, Boyle, Alexandra, Miller, Cynthia, Trotman, Lloyd, Delaleu, Nicolas, Fassan, Matteo, Moch, Holger, Viero, Gabriella, de Bono, Johann, Alimonti, Andrea
Internally Controlled and Dynamic Optical Measures of Functional Tumor Biology
4 Apr 2023 | Analytical Chemistry | 95(13):5661-5670
Chung, Taemoon, Garcia, Libia, Swamynathan, Manojit, Froeling, Fieke, Trotman, Lloyd, Tuveson, David, Lyons, Scott
PP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancers
3 Dec 2022 | Molecular Oncology
Aakula, Anna, Isomursu, Aleksi, Rupp, Christian, Erickson, Andrew, Gupta, Nikhil, Kauko, Otto, Shah, Pragya, Padzik, Artur, Pokharel, Yuba, Kaur, Amanpreet, Li, Song-Ping, Trotman, Lloyd, Taimen, Pekka, Rannikko, Antti, Lammerding, Jan, Paatero, Ilkka, Mirtti, Tuomas, Ivaska, Johanna, Westermarck, Jukka
Internally-controlled and dynamic optical measures of functional tumor biology
31 May 2022 | bioRxiv
Chung, Taemoon, Garcia, Libia, Swamynathan, Manojit, Froeling, Fieke, Trotman, Lloyd, Tuveson, David, Lyons, Scott
Combined whole-organ imaging at single-cell resolution and immunohistochemical analysis of prostate cancer and its liver and brain metastases.
16 Nov 2021 | Cell Reports | 37(7):110027
Taranda, Julian, Mathew, Grinu, Watrud, Kaitlin, El-Amine, Nour, Lee, Matthew, Elowsky, Corey, Bludova, Anastasiia, Escobar Avelar, Sintia, Nowak, Dawid, Wee, Tse-Luen, Wilkinson, John, Trotman, Lloyd, Osten, Pavel
Advances in preclinical evaluation of experimental antibody-drug conjugates.
4 Jul 2021 | Cancer Drug Resistance | 4:745-754
Lyons, Scott, Plenker, Dennis, Trotman, Lloyd
SOAT1 promotes mevalonate pathway dependency in pancreatic cancer
7 Jul 2020 | Journal of Experimental Medicine | 217(9)
Oni, T, Biffi, G, Baker, L, Hao, Y, Tonelli, C, Somerville, T, Deschênes, A, Belleau, P, Hwang, C, Sánchez-Rivera, F, Cox, H, Brosnan, E, Doshi, A, Lumia, R, Khaledi, K, Park, Y, Trotman, L, Lowe, S, Krasnitz, A, Vakoc, C, Tuveson, D
Competence against insufficiency: Why are men mostly safe from a rare and deadly prostate cancer?
Jun 2020 | Journal of Experimental Medicine | 217(6):e20200087
Mathew, G, Trotman, L
Roadmap for the Emerging Field of Cancer Neuroscience
16 Apr 2020 | Cell | 181(2):219-222
Monje, M, Borniger, J, D'Silva, N, Deneen, B, Dirks, P, Fattahi, F, Frenette, P, Garzia, L, Gutmann, D, Hanahan, D, Hervey-Jumper, S, Hondermarck, H, Hurov, J, Kepecs, A, Knox, S, Lloyd, A, Magnon, C, Saloman, J, Segal, R, Sloan, E, Sun, X, Taylor, M, Tracey, K, Trotman, L, Tuveson, D, Wang, T, White, R, Winkler, F
PTEN: Bridging Endocytosis and Signaling
9 Dec 2019 | Cold Spring Harbor Perspectives in Medicine
Lee, M, Trotman, L